Fresh analysis suggests that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end traditional diet and exercise plans.
Published data in a leading health publication demonstrates that while obese people often shed about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these medications need to be informed of the danger of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of regain means a reversion to original weight within about 18 months.
Weighing Therapies
The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of these new drugs with other pills.
The team emphasize that people who lose weight through dieting usually experience a less rapid creep back—around 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Doctors suggest the mode of action of the drugs explains the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement leads to hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, considering the likelihood of weight regain, the treatment might need to be life-long.
This opinion is echoed by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," similar to managing conditions like hypertension.
User Accounts
Users who have discontinued the medication explain a powerful return of cravings.
"I experienced a switch that goes on and I was suddenly ravenous," recalled an individual.
The struggle is compounded if individuals have not established sustainable dietary or behavioural modifications during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic solution and long-term success hinges on ongoing behavioural management.
